Russell Investments Group Ltd. Sells 1,353 Shares of Medifast, Inc. (NYSE:MED)

2025-04-26T07:26:52Z

Russell Investments Group Ltd. reduced its stake in shares of Medifast, Inc. (NYSE:MED – Free Report) by 12.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,113 shares of the specialty retailer’s stock after selling 1,353 shares during the quarter. Russell Investments Group Ltd.’s holdings in Medifast were worth $161,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of MED. JPMorgan Chase & Co. increased its stake in Medifast by 156.1% during the third quarter. JPMorgan Chase & Co. now owns 57,455 shares of the specialty retailer’s stock valued at $1,100,000 after acquiring an additional 35,017 shares during the period. Amundi bought a new stake in shares of Medifast during the fourth quarter valued at approximately $374,000. American Century Companies Inc. raised its stake in shares of Medifast by 3.4% in the fourth quarter. American Century Companies Inc. now owns 244,185 shares of the specialty retailer’s stock valued at $4,303,000 after purchasing an additional 8,058 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Medifast by 2,308.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 11,442 shares of the specialty retailer’s stock worth $202,000 after purchasing an additional 10,967 shares during the period. Finally, Landscape Capital Management L.L.C. acquired a new stake in Medifast during the fourth quarter worth $577,000. 95.51% of the stock is owned by institutional investors.

Get Medifast alerts:

Medifast Trading Up 1.2 %

Shares of NYSE MED opened at $12.32 on Friday. Medifast, Inc. has a 1-year low of $11.57 and a 1-year high of $36.30. The company has a 50-day moving average of $13.54 and a two-hundred day moving average of $16.17. The company has a market cap of $134.76 million, a PE ratio of 68.44 and a beta of 1.05.

Wall Street Analyst Weigh In

Medifast ( NYSE:MED Get Free Report ) last posted its quarterly earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.26. Medifast had a return on equity of 10.64% and a net margin of 0.35%. The business had revenue of $119.00 million for the quarter, compared to analysts’ expectations of $114.25 million. As a group, equities research analysts forecast that Medifast, Inc. will post 0.51 earnings per share for the current year.

Separately, DA Davidson decreased their price objective on Medifast from $17.00 to $16.50 and set a “neutral” rating on the stock in a report on Wednesday, February 19th.

View Our Latest Research Report on Medifast

About Medifast

(Free Report)

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.